‘NRG-GY009’ of page ‘NRG-GY009’
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer This study is currently ONLY OPEN TO SAFETY-LEAD IN Participating Institutions Principal Investigator/Co-Principal Investigator Alexandra Snyder Charen, M.D./Carol Aghajanian, M.D. Primary Objective Safety Lead-in: […]
Read More